𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Expression of cathepsins B and S in the progression of prostate carcinoma

✍ Scribed by Pedro L. Fernández; Xavier Farré; Alfons Nadal; Eva Fernández; Nerea Peiró; Bonnie F. Sloane; Guo-Ping Shi; Harold A. Chapman; Elías Campo; Antonio Cardesa


Publisher
John Wiley and Sons
Year
2001
Tongue
French
Weight
352 KB
Volume
95
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Dedifferentiation in the metastatic prog
✍ Liang Cheng; Jeff Slezak; Erik J. Bergstralh; John C. Cheville; Susan Sweat; Hor 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 490 KB 👁 2 views

## BACKGROUND. Dedifferentiation is a distinctive feature of cancer progression. Detailed histologic analysis of primary prostate carcinoma and synchronous lymph node metastases may improve our understanding of the complex process of cancer progression and metastasis. ## METHODS. The authors s

Expression of p27/kip1 is down-regulated
✍ Fern�ndez, Pedro L.; Arce, Yolanda; Farr�, Xavier; Mart�nez, Antonio; Nadal, Alf 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 238 KB 👁 1 views

p27 Kip1 is a cyclin-dependent kinase inhibitor whose down-regulation has been observed in several tumour models, including breast, colorectal, and gastric carcinomas. The purpose of this study was to assess p27 Kip1 protein expression in normal and benign prostatic epithelia as well as the possible

Modulation of invasive properties of mur
✍ Sogué Coulibaly; Herwig Schwihla; Magnus Abrahamson; Adriana Albini; Christa Cer 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 122 KB

Murine SCC-VII squamous carcinoma cells have the capacity to penetrate reconstituted basement membranes (Matrigel) in vitro. The invasion of Matrigel layers by SCC-VII cells was significantly reduced by E-64, a specific inhibitor of lysosomal cysteine proteinases. The cathepsin-B-selective E-64 deri

Expression, structure, and function of a
✍ Culig, Zoran; Hobisch, Alfred; Hittmair, Anton; Peterziel, Heike; Cato, Andrew C 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 53 KB 👁 1 views

## BACKGROUND. Endocrine therapy for prostate cancer aims to reduce the levels of circulating androgen or to inhibit androgen action by blocking the androgen receptor in the prostate, or both. Studies in various animal and human prostate cancer models suggested that there may be a downregulation o